Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB1801 versus Taxotere in previously treated advanced non-small cell lung cancer
CTR20231419Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel, docetaxel in non-small cell lung cancer (NSCLC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jun 2023; status: active.
02
Drugs
albumin-bound docetaxeldocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231419.